Rapid detection of ampicillin resistance in Escherichia coli by quantitative mass spectrometry.
Early targeted antimicrobial therapy helps decrease costs and prevents the spread of antimicrobial resistance, including in Escherichia coli, the most frequent Gram-negative bacterium that causes sepsis. Therefore, rapid susceptibility testing represents the major prerequisite for knowledge-based successful antimicrobial treatment. To accelerate testing for antibiotic susceptibility, we have developed a new mass spectrometry-based assay for antibiotic susceptibility testing (MAAST). For proof of principle, we present an ampicillin susceptibility test for E. coli with a turnaround time of 90 min upon growth detection.
Institute for Clinical Chemistry, Medical Faculty Mannheim of University of Heidelberg, Heidelberg, Germany. alexander.grundt@umm.de
A
A
Grundt
P
P
Findeisen
T
T
Miethke
E
E
Jäger
P
P
Ahmad-Nejad
M
M
Neumaier
D000667:Ampicillin / Q000494:pharmacology*; D000668:Ampicillin Resistance; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D008826:Microbial Sensitivity Tests / Q000379:methods; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000667:Ampicillin